In the US, IMS Health has acquired San Francisco-based software firm DecisionView, which helps life sciences organizations plan and track patient enrollment for clinical trials around the world. Terms of the deal were not disclosed.
DecisionView’s flagship StudyOptimzer solution helps clinical trial organizations to plan, forecast and track patient enrollment, while its Enrollment Benchmarks tool aggregates cross-industry performance data from clinical trials.
DecisionView will become part of IMS’s Value Solutions business. IMS’ own health outcomes, provider, and anonymized patient data will be integrated with DecisionView’s predictive analytics and performance data gathered from more than 1,200 clinical studies across 90+ countries. IMS says this combination will enable clinical trial sponsors and research organizations to base site selection and payment enrollment decisions on real-world data and benchmarks.
Linda Drumright (pictured), DecisionView President and CEO, says the combination ‘opens up a whole new set of possibilities for clinical trial decision-making’ and adds: ‘Our clients recognize the need for more data and analytics to guide their clinical trial enrollment and performance management activities.’
Web sites: www.imshealth.com